Algonomics Included in MSCI Korea Small Cap Index

"Expecting Improved Capital Inflows Through Global Passive Funds"

Algonomics announced on May 29 that it has been officially included in the MSCI Korea Small Cap Index, a global stock market index by Morgan Stanley Capital International (MSCI). The inclusion will take effect after the market closes on the same day.

The MSCI index is recognized as one of the leading global investment benchmarks. It is widely used by global institutional investors and passive funds as a key investment standard, with constituent stocks adjusted through regular reviews every February, May, August, and November.

Algonomics company logo image. Algonomics

Algonomics was selected for inclusion in the May review after meeting criteria such as market capitalization and liquidity. The company stated that it expects the inclusion to lead to inflows of global passive funds tracking the MSCI index and to expand its transaction base.

Algonomics is currently developing next-generation gene therapies based on its proprietary ribozyme-based RNA editing platform. Its leading pipeline, the anti-cancer gene therapy 'Tasfitimagen Advec (RZ-001),' recently received Regenerative Medicine Advanced Therapy (RMAT) designation from the U.S. Food and Drug Administration (FDA).

The company has also presented relevant clinical and non-clinical data at the American Association for Cancer Research (AACR) and the American Society of Gene & Cell Therapy (ASGCT).

This content was produced with the assistance of AI translation services.